Avacta says Covid-19 test shows 'excellent' performance in clinical studies

Writer,

Affimer biotherapeutics and reagents developer Avacta said it had received the first data showing 'excellent performance' of its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK.

'These data show excellent performance of the test in identifying patients with an infectious viral load and no false positive results,' the company said.

'On the basis of these initial clinical studies, the lateral flow test shows very good sensitivity in the infectious range of viral loads including at the lower infectious loads with Ct values of 23-26 which compares very favourably with the data reported in the Liverpool Covid SMART Pilot Study report,' it added.

Following the initial data, the company said it would now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.

At 9:22am: (LON:AVCT) Avacta Group PLC share price was 0p at 111.5p


Related content

Avacta signs distribution agreement with ABCAM for Covid-19 Affimer reagents

Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents.

Under the worldwide, non-exclusive...

Tue, 06/04/2021 - 09:26


Avacta signs diagnostic licensing deal with Biokit

Cancer therapies and diagnostics group Avacta said it had entered into a license agreement with Biokit, a Werfen company, to incorporate its affimer reagents into...

Tue, 09/03/2021 - 09:55


Avacta targets Covid-19 test kit launch by end of Q1; cancer drug trial to get underway by mid-2021

Avacta said it was targeting a launch of its Covid-19 test kit by around the end of the first quarter of this year, as the...

Wed, 24/02/2021 - 09:19


Avacta wins approval from UK health authorities for cancer drug trial

Affimer biotherapeutics and reagents group Avacta said it had received approval from UK health authorities to move ahead with with its trial of its lead...

Thu, 18/02/2021 - 09:55


Avacta teamsp up with Mologic to market Covid-19 tests

Biotherapeutics company Avacta said it had entered into a commercial partnership with Mologic to market the company's SARS-CoV-2 lateral flow rapid antigen test.

Avacta...

Mon, 08/02/2021 - 09:50